Acumen Pharmaceuticals, Inc. (ABOS)

SEC fundamentals · as filed in 10-Q FY2026, period ended Sep 30, 2026 · updated Oct 28, 2026

Verified against EDGAR
Total Assets
$85.6M
Stockholders' Equity
$34.6M
Cash & Equivalents
$53.1M
Long-Term Debt
$5.9M

as filed in 10-Q FY2026, period ended Sep 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Sep 30, 2026, Acumen Pharmaceuticals, Inc. reported net income of -$25.4M and total assets of $85.6M. Every figure below is taken directly from Acumen Pharmaceuticals, Inc.'s SEC filings: each links to the source document on EDGAR.

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025—-$121.3M
FY2024—-$102.3M
FY2023—-$52.4M
FY2022—-$42.9M
FY2021—-$100.6M
FY2020—-$7.3M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KOct 26, 2026on EDGAR ↗
10-QOct 26, 2026on EDGAR ↗
8-KSep 16, 2026on EDGAR ↗
8-KAug 12, 2026on EDGAR ↗
10-QAug 12, 2026on EDGAR ↗
8-KJun 16, 2026on EDGAR ↗
8-KJun 3, 2026on EDGAR ↗
10-QMay 12, 2026on EDGAR ↗
8-KMay 12, 2026on EDGAR ↗
DEF 14AApr 23, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Sep 30, 2026 · 10-Q

Total Assets$85.6Msource ↗
Stockholders’ Equity$34.6Msource ↗
Cash & Equivalents$53.1Msource ↗
Long-Term Debt$5.9Msource ↗

Income Statement

10-Q (quarterly) · period ended Sep 30, 2026

Revenue—source ↗
Net Income-$25.4Msource ↗
Operating Income-$25.8Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$21.1Msource ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Sep 30, 2026

EPS (diluted)$-0.35source ↗
EPS (basic)$-0.35source ↗
Shares Outstanding72.3Msource ↗
Cash from Operations-$26.7Msource ↗
Cash from Financing-$5.0Msource ↗
Cash from Investing$25.3Msource ↗

Insider activity

Form 4 open-market activity, last 180 days

Buys
0
Sells
4
Net shares
-38.7K

Restatement history

Point-in-time

No material restatements detected across 138 annual fact-keys: this company's as-filed numbers have held between filings. Point-in-time and as-of history are available via the API.

Deeper fundamentals

A free API key reaches ABOS’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Get a free API key →See plans

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/ABOS

MCP tool: get_sec_fundamentals ticker=ABOS

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/ABOS/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=ABOS as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/ABOS/history

MCP tool: get_fundamentals_history ticker=ABOS

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/financial-health/ABOS

MCP tool: get_financial_health ticker=ABOS

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.